Gensight Biologics SA Total Liabilities
Gensight Biologics SA total liabilities. Based on the latest financial reports, Gensight Biologics SA (SIGHT) has total liabilities worth €33.20 Million EUR (≈ $38.81 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Gensight Biologics SA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Gensight Biologics SA (2012–2025)
Total liabilities of Gensight Biologics SA from 2012 to 2025. This chart illustrates how Gensight Biologics SA's total liabilities have evolved over time, based on quarterly financial data.
Gensight Biologics SA Competitors by Total Liabilities
The table below lists competitors of Gensight Biologics SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AJ Advance Technology Public Company Limited
BK:AJA
|
Thailand | ฿117.86 Million |
|
Seres Therapeutics Inc
NASDAQ:MCRB
|
USA | $67.05 Million |
|
Puncak Niaga Holdings Bhd
KLSE:6807
|
Malaysia | RM1.49 Billion |
|
SCI Electric Public Company Limited
BK:SCI
|
Thailand | ฿911.77 Million |
|
INSPIREMD 1/18 DL-0001
F:II2
|
Germany | €14.20 Million |
|
Delko S.A.
WAR:DEL
|
Poland | zł174.50 Million |
|
DarkHorse Technologies Inc.
NASDAQ:DRK
|
USA | $7.99 Million |
|
Eason & Co Public Company Limited
BK:EASON
|
Thailand | ฿219.28 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Gensight Biologics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Gensight Biologics SA (SIGHT) total assets.
Liquidity & Leverage Metrics
Gensight Biologics SA Total Liabilities Ratios Explained
Gensight Biologics SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gensight Biologics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gensight Biologics SA (2012–2025)
The table below shows the annual total liabilities of Gensight Biologics SA from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €33.20 Million ≈ $38.81 Million |
-11.89% |
| 2024-12-31 | €37.68 Million ≈ $44.05 Million |
-5.42% |
| 2023-12-31 | €39.83 Million ≈ $46.57 Million |
-3.36% |
| 2022-12-31 | €41.22 Million ≈ $48.19 Million |
+1.38% |
| 2021-12-31 | €40.66 Million ≈ $47.53 Million |
+13.91% |
| 2020-12-31 | €35.69 Million ≈ $41.73 Million |
+72.13% |
| 2019-12-31 | €20.74 Million ≈ $24.24 Million |
+58.19% |
| 2018-12-31 | €13.11 Million ≈ $15.33 Million |
+81.67% |
| 2017-12-31 | €7.22 Million ≈ $8.44 Million |
+22.51% |
| 2016-12-31 | €5.89 Million ≈ $6.89 Million |
-15.66% |
| 2015-12-31 | €6.98 Million ≈ $8.16 Million |
+64.81% |
| 2014-12-31 | €4.24 Million ≈ $4.95 Million |
+122.31% |
| 2013-12-31 | €1.91 Million ≈ $2.23 Million |
+1399.90% |
| 2012-12-31 | €127.08K ≈ $148.57K |
-- |
About Gensight Biologics SA
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV… Read more